title: Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma.
abstract: The aim of this study was to compare prospectively the accuracy of whole-body positron emission tomography (PET), CT and MRI in diagnosing primary and recurrent ovarian cancer. Nineteen patients (age range 23-76 years) were recruited with suspicious ovarian lesions at presentation (n = 8) or follow-up for recurrence (n = 11). All patients were scheduled for laparotomy and histological confirmation. Whole-body PET with FDG, contrast-enhanced spiral CT of the abdomen, including the pelvis, and MRI of the entire abdomen were performed. Each imaging study was evaluated separately. Imaging findings were correlated with histopathological diagnosis. The sensitivity, specificity and accuracy for lesion characterization in patients with suspicious ovarian lesions (n = 7) were, respectively: 100, 67 and 86% for PET; 100, 67 and 86% for CT; and 100, 100 and 100% for MRI. For the diagnosis of recurrent disease (n = 10), PET had a sensitivity of 100%, specificity of 50% and accuracy of 90%. The PET technique was the only technique which correctly identified a single transverse colon metastasis. Results for CT were 40, 50 and 43%, and for MRI 86, 100 and 89%, respectively. No statistically significant difference was seen. Neither FDG PET nor CT nor MRI can replace surgery in the detection of microscopic peritoneal disease. No statistically significant difference was observed for the investigated imaging modalities with regard to lesion characterization or detection of recurrent disease; thus, the methods are permissible alternatives. The PET technique, however, has the drawback of less accurate spatial assignment of small lesions compared with CT and MRI.
authors.affiliation: Department of Radiology, Institute of Diagnostic Radiology, University Hospital Zurich, Switzerland.
authors.forename: R A
authors.initials: RA
authors.lastname: Kubik-Huch
authors.forename: W
authors.initials: W
authors.lastname: Dörffler
authors.forename: G K
authors.initials: GK
authors.lastname: von Schulthess
authors.forename: B
authors.initials: B
authors.lastname: Marincek
authors.forename: O R
authors.initials: OR
authors.lastname: Köchli
authors.forename: B
authors.initials: B
authors.lastname: Seifert
authors.forename: U
authors.initials: U
authors.lastname: Haller
authors.forename: H C
authors.initials: HC
authors.lastname: Steinert
mesh_terms: D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000175:diagnosis* / Q000556:secondary; D003110:Colonic Neoplasms / Q000175:diagnosis / Q000556:secondary; D003287:Contrast Media; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D007813:Laparotomy; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis*; D010051:Ovarian Neoplasms / Q000175:diagnosis*; D010534:Peritoneal Neoplasms / Q000175:diagnosis / Q000556:secondary; D011446:Prospective Studies; D011860:Radiography, Abdominal; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed; D014915:Whole-Body Counting
chemical_list: D003287:Contrast Media; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18